Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

Evaluation of Interindividual Human Variation in Bioactivation and DNA Adduct Formation of Estragole in Liver Predicted by Physiologically Based Kinetic/Dynamic and Monte Carlo Modeling.

Punt A, Paini A, Spenkelink A, Scholz G, Schilter B, van Bladeren PJ, Rietjens IM.

Chem Res Toxicol. 2016 Apr 18;29(4):659-68. doi: 10.1021/acs.chemrestox.5b00493. Epub 2016 Mar 23.

PMID:
26952143
2.

Effect of Glucuronidation on the Potential of Kaempferol to Inhibit Serine/Threonine Protein Kinases.

Beekmann K, de Haan LH, Actis-Goretta L, van Bladeren PJ, Rietjens IM.

J Agric Food Chem. 2016 Feb 17;64(6):1256-63. doi: 10.1021/acs.jafc.5b05456. Epub 2016 Feb 3.

PMID:
26808477
3.

The effect of glucuronidation on isoflavone induced estrogen receptor (ER)α and ERβ mediated coregulator interactions.

Beekmann K, de Haan LH, Actis-Goretta L, Houtman R, van Bladeren PJ, Rietjens IM.

J Steroid Biochem Mol Biol. 2015 Nov;154:245-53. doi: 10.1016/j.jsbmb.2015.09.002. Epub 2015 Sep 7.

PMID:
26361015
4.

The effect of quercetin and kaempferol aglycones and glucuronides on peroxisome proliferator-activated receptor-gamma (PPAR-γ).

Beekmann K, Rubió L, de Haan LH, Actis-Goretta L, van der Burg B, van Bladeren PJ, Rietjens IM.

Food Funct. 2015 Apr;6(4):1098-107. doi: 10.1039/c5fo00076a.

PMID:
25765892
5.

Evaluation of the interindividual human variation in bioactivation of methyleugenol using physiologically based kinetic modeling and Monte Carlo simulations.

Al-Subeihi AA, Alhusainy W, Kiwamoto R, Spenkelink B, van Bladeren PJ, Rietjens IM, Punt A.

Toxicol Appl Pharmacol. 2015 Mar 1;283(2):117-26. doi: 10.1016/j.taap.2014.12.009. Epub 2014 Dec 27.

PMID:
25549870
6.

Malabaricone C-containing mace extract inhibits safrole bioactivation and DNA adduct formation both in vitro and in vivo.

Martati E, Boonpawa R, van den Berg JH, Paini A, Spenkelink A, Punt A, Vervoort J, van Bladeren PJ, Rietjens IM.

Food Chem Toxicol. 2014 Apr;66:373-84. doi: 10.1016/j.fct.2014.01.043. Epub 2014 Feb 6.

PMID:
24508526
7.

In vivo validation and physiologically based biokinetic modeling of the inhibition of SULT-mediated estragole DNA adduct formation in the liver of male Sprague-Dawley rats by the basil flavonoid nevadensin.

Alhusainy W, Paini A, van den Berg JH, Punt A, Scholz G, Schilter B, van Bladeren PJ, Taylor S, Adams TB, Rietjens IM.

Mol Nutr Food Res. 2013 Nov;57(11):1969-78. doi: 10.1002/mnfr.201300144. Epub 2013 Jul 26.

PMID:
23894034
8.

Inhibition of methyleugenol bioactivation by the herb-based constituent nevadensin and prediction of possible in vivo consequences using physiologically based kinetic modeling.

Al-Subeihi AA, Alhusainy W, Paini A, Punt A, Vervoort J, van Bladeren PJ, Rietjens IM.

Food Chem Toxicol. 2013 Sep;59:564-71. doi: 10.1016/j.fct.2013.06.043. Epub 2013 Jul 4.

PMID:
23831728
9.

Effects of pre-exercise sucralose ingestion on carbohydrate oxidation during exercise.

Stellingwerff T, Godin JP, Beaumont M, Tavenard A, Grathwohl D, van Bladeren PJ, Kapp AF, le Coutre J, Damak S.

Int J Sport Nutr Exerc Metab. 2013 Dec;23(6):584-92. Epub 2013 May 20.

PMID:
23689036
10.

In vivo validation of DNA adduct formation by estragole in rats predicted by physiologically based biodynamic modelling.

Paini A, Punt A, Scholz G, Gremaud E, Spenkelink B, Alink G, Schilter B, van Bladeren PJ, Rietjens IM.

Mutagenesis. 2012 Nov;27(6):653-63. doi: 10.1093/mutage/ges031. Epub 2012 Jul 27.

PMID:
22844077
11.

A state-of-the-art overview of the effect of metabolic conjugation on the biological activity of flavonoids.

Beekmann K, Actis-Goretta L, van Bladeren PJ, Dionisi F, Destaillats F, Rietjens IM.

Food Funct. 2012 Oct;3(10):1008-18. Epub 2012 Jul 12. Review.

PMID:
22751838
12.

Matrix modulation of the bioactivation of estragole by constituents of different alkenylbenzene-containing herbs and spices and physiologically based biokinetic modeling of possible in vivo effects.

Alhusainy W, van den Berg SJ, Paini A, Campana A, Asselman M, Spenkelink A, Punt A, Scholz G, Schilter B, Adams TB, van Bladeren PJ, Rietjens IM.

Toxicol Sci. 2012 Sep;129(1):174-87. doi: 10.1093/toxsci/kfs196. Epub 2012 May 30.

PMID:
22649189
13.

Physiologically based biokinetic (PBBK) modeling of safrole bioactivation and detoxification in humans as compared with rats.

Martati E, Boersma MG, Spenkelink A, Khadka DB, van Bladeren PJ, Rietjens IM, Punt A.

Toxicol Sci. 2012 Aug;128(2):301-16. doi: 10.1093/toxsci/kfs174. Epub 2012 May 14.

PMID:
22588462
14.

Physiologically based kinetic modeling of bioactivation and detoxification of the alkenylbenzene methyleugenol in human as compared with rat.

Al-Subeihi AA, Spenkelink B, Punt A, Boersma MG, van Bladeren PJ, Rietjens IM.

Toxicol Appl Pharmacol. 2012 May 1;260(3):271-84. doi: 10.1016/j.taap.2012.03.005. Epub 2012 Mar 14.

PMID:
22445790
15.

The Extended Nutrigenomics - Understanding the Interplay between the Genomes of Food, Gut Microbes, and Human Host.

Kussmann M, Van Bladeren PJ.

Front Genet. 2011 May 20;2:21. doi: 10.3389/fgene.2011.00021. eCollection 2011.

16.

Interaction of hesperetin glucuronide conjugates with human BCRP, MRP2 and MRP3 as detected in membrane vesicles of overexpressing baculovirus-infected Sf9 cells.

Brand W, Oosterhuis B, Krajcsi P, Barron D, Dionisi F, van Bladeren PJ, Rietjens IM, Williamson G.

Biopharm Drug Dispos. 2011 Dec;32(9):530-5. doi: 10.1002/bdd.780. Epub 2011 Nov 21.

PMID:
22083890
17.

Quantitative comparison between in vivo DNA adduct formation from exposure to selected DNA-reactive carcinogens, natural background levels of DNA adduct formation and tumour incidence in rodent bioassays.

Paini A, Scholz G, Marin-Kuan M, Schilter B, O'Brien J, van Bladeren PJ, Rietjens IM.

Mutagenesis. 2011 Sep;26(5):605-18. doi: 10.1093/mutage/ger022. Epub 2011 Jun 3.

PMID:
21642616
18.

Physiologically based biokinetic (PBBK) model for safrole bioactivation and detoxification in rats.

Martati E, Boersma MG, Spenkelink A, Khadka DB, Punt A, Vervoort J, van Bladeren PJ, Rietjens IM.

Chem Res Toxicol. 2011 Jun 20;24(6):818-34. doi: 10.1021/tx200032m. Epub 2011 Apr 8.

PMID:
21446753
19.

Physiologically based biokinetic model of bioactivation and detoxification of the alkenylbenzene methyleugenol in rat.

Al-Subeihi AA, Spenkelink B, Rachmawati N, Boersma MG, Punt A, Vervoort J, van Bladeren PJ, Rietjens IM.

Toxicol In Vitro. 2011 Feb;25(1):267-85. doi: 10.1016/j.tiv.2010.08.019. Epub 2010 Sep 7.

PMID:
20828604
20.

Stereoselective conjugation, transport and bioactivity of s- and R-hesperetin enantiomers in vitro.

Brand W, Shao J, Hoek-van den Hil EF, van Elk KN, Spenkelink B, de Haan LH, Rein MJ, Dionisi F, Williamson G, van Bladeren PJ, Rietjens IM.

J Agric Food Chem. 2010 May 26;58(10):6119-25. doi: 10.1021/jf1008617.

PMID:
20441166
21.

Identification of nevadensin as an important herb-based constituent inhibiting estragole bioactivation and physiology-based biokinetic modeling of its possible in vivo effect.

Alhusainy W, Paini A, Punt A, Louisse J, Spenkelink A, Vervoort J, Delatour T, Scholz G, Schilter B, Adams T, van Bladeren PJ, Rietjens IM.

Toxicol Appl Pharmacol. 2010 Jun 1;245(2):179-90. doi: 10.1016/j.taap.2010.02.017. Epub 2010 Mar 11. Erratum in: Toxicol Appl Pharmacol. 2010 Sep 15;247(3):250.

PMID:
20226806
22.

A physiologically based biodynamic (PBBD) model for estragole DNA binding in rat liver based on in vitro kinetic data and estragole DNA adduct formation in primary hepatocytes.

Paini A, Punt A, Viton F, Scholz G, Delatour T, Marin-Kuan M, Schilter B, van Bladeren PJ, Rietjens IM.

Toxicol Appl Pharmacol. 2010 May 15;245(1):57-66. doi: 10.1016/j.taap.2010.01.016. Epub 2010 Feb 6.

PMID:
20144636
23.

The effect of co-administered flavonoids on the metabolism of hesperetin and the disposition of its metabolites in Caco-2 cell monolayers.

Brand W, Padilla B, van Bladeren PJ, Williamson G, Rietjens IM.

Mol Nutr Food Res. 2010 Jun;54(6):851-60. doi: 10.1002/mnfr.200900183.

PMID:
20112299
24.

Phase II metabolism of hesperetin by individual UDP-glucuronosyltransferases and sulfotransferases and rat and human tissue samples.

Brand W, Boersma MG, Bik H, Hoek-van den Hil EF, Vervoort J, Barron D, Meinl W, Glatt H, Williamson G, van Bladeren PJ, Rietjens IM.

Drug Metab Dispos. 2010 Apr;38(4):617-25. doi: 10.1124/dmd.109.031047. Epub 2010 Jan 7.

PMID:
20056724
25.

In silico methods for physiologically based biokinetic models describing bioactivation and detoxification of coumarin and estragole: implications for risk assessment.

Rietjens IM, Punt A, Schilter B, Scholz G, Delatour T, van Bladeren PJ.

Mol Nutr Food Res. 2010 Feb;54(2):195-207. doi: 10.1002/mnfr.200900211. Review.

PMID:
19943261
26.

Evaluation of human interindividual variation in bioactivation of estragole using physiologically based biokinetic modeling.

Punt A, Jeurissen SM, Boersma MG, Delatour T, Scholz G, Schilter B, van Bladeren PJ, Rietjens IM.

Toxicol Sci. 2010 Feb;113(2):337-48. doi: 10.1093/toxsci/kfp272. Epub 2009 Nov 17.

PMID:
19920071
27.

Use of physiologically based biokinetic (PBBK) modeling to study estragole bioactivation and detoxification in humans as compared with male rats.

Punt A, Paini A, Boersma MG, Freidig AP, Delatour T, Scholz G, Schilter B, van Bladeren PJ, Rietjens IM.

Toxicol Sci. 2009 Aug;110(2):255-69. doi: 10.1093/toxsci/kfp102. Epub 2009 May 15.

28.

Potency of isothiocyanates to induce luciferase reporter gene expression via the electrophile-responsive element from murine glutathione S-transferase Ya.

Vermeulen M, Boerboom AM, Blankvoort BM, Aarts JM, Rietjens IM, van Bladeren PJ, Vaes WH.

Toxicol In Vitro. 2009 Jun;23(4):617-21. doi: 10.1016/j.tiv.2009.02.005. Epub 2009 Feb 20.

PMID:
19232536
29.

Glutathione-dependent interaction of heavy metal compounds with multidrug resistance proteins MRP1 and MRP2.

Wortelboer HM, Balvers MG, Usta M, van Bladeren PJ, Cnubben NH.

Environ Toxicol Pharmacol. 2008 Jul;26(1):102-8. doi: 10.1016/j.etap.2008.02.006. Epub 2008 Feb 23.

PMID:
21783896
30.

A physiologically based biokinetic (PBBK) model for estragole bioactivation and detoxification in rat.

Punt A, Freidig AP, Delatour T, Scholz G, Boersma MG, Schilter B, van Bladeren PJ, Rietjens IM.

Toxicol Appl Pharmacol. 2008 Sep 1;231(2):248-59. doi: 10.1016/j.taap.2008.04.011. Epub 2008 Apr 27.

PMID:
18539307
31.

Metabolism and transport of the citrus flavonoid hesperetin in Caco-2 cell monolayers.

Brand W, van der Wel PA, Rein MJ, Barron D, Williamson G, van Bladeren PJ, Rietjens IM.

Drug Metab Dispos. 2008 Sep;36(9):1794-802. doi: 10.1124/dmd.107.019943. Epub 2008 May 30.

PMID:
18515333
32.

Human glutathione S-transferase-mediated glutathione conjugation of curcumin and efflux of these conjugates in Caco-2 cells.

Usta M, Wortelboer HM, Vervoort J, Boersma MG, Rietjens IM, van Bladeren PJ, Cnubben NH.

Chem Res Toxicol. 2007 Dec;20(12):1895-902. Epub 2007 Nov 1.

PMID:
17975885
33.
34.

Functional peptides by genome reverse engineering.

Grigorov MG, van Bladeren PJ.

Curr Opin Drug Discov Devel. 2007 May;10(3):341-6. Review.

PMID:
17554861
35.

Human cytochrome p450 enzyme specificity for the bioactivation of estragole and related alkenylbenzenes.

Jeurissen SM, Punt A, Boersma MG, Bogaards JJ, Fiamegos YC, Schilter B, van Bladeren PJ, Cnubben NH, Rietjens IM.

Chem Res Toxicol. 2007 May;20(5):798-806. Epub 2007 Apr 4.

PMID:
17407329
36.

Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients.

Brand W, Schutte ME, Williamson G, van Zanden JJ, Cnubben NH, Groten JP, van Bladeren PJ, Rietjens IM.

Biomed Pharmacother. 2006 Nov;60(9):508-19. Epub 2006 Sep 1. Review.

PMID:
16978825
37.

Metabolism of ATP-binding cassette drug transporter inhibitors: complicating factor for multidrug resistance.

Cnubben NH, Wortelboer HM, van Zanden JJ, Rietjens IM, van Bladeren PJ.

Expert Opin Drug Metab Toxicol. 2005 Aug;1(2):219-32. Review.

PMID:
16922638
38.

Association between consumption of cruciferous vegetables and condiments and excretion in urine of isothiocyanate mercapturic acids.

Vermeulen M, van den Berg R, Freidig AP, van Bladeren PJ, Vaes WH.

J Agric Food Chem. 2006 Jul 26;54(15):5350-8.

PMID:
16848516
39.

Newly constructed stable reporter cell lines for mechanistic studies on electrophile-responsive element-mediated gene expression reveal a role for flavonoid planarity.

Boerboom AM, Vermeulen M, van der Woude H, Bremer BI, Lee-Hilz YY, Kampman E, van Bladeren PJ, Rietjens IM, Aarts JM.

Biochem Pharmacol. 2006 Jul 14;72(2):217-26. Epub 2006 Apr 25.

PMID:
16756964
40.

Profiles of metabolites and gene expression in rats with chemically induced hepatic necrosis.

Heijne WH, Lamers RJ, van Bladeren PJ, Groten JP, van Nesselrooij JH, van Ommen B.

Toxicol Pathol. 2005;33(4):425-33.

PMID:
16036859
41.

Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine resistance by the flavonoid myricetin.

van Zanden JJ, de Mul A, Wortelboer HM, Usta M, van Bladeren PJ, Rietjens IM, Cnubben NH.

Biochem Pharmacol. 2005 Jun 1;69(11):1657-65. Epub 2005 Apr 13.

PMID:
15896345
42.

Inhibition of multidrug resistance proteins MRP1 and MRP2 by a series of alpha,beta-unsaturated carbonyl compounds.

Wortelboer HM, Usta M, van Zanden JJ, van Bladeren PJ, Rietjens IM, Cnubben NH.

Biochem Pharmacol. 2005 Jun 15;69(12):1879-90.

PMID:
15885658
43.

Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro.

van Erk MJ, Roepman P, van der Lende TR, Stierum RH, Aarts JM, van Bladeren PJ, van Ommen B.

Eur J Nutr. 2005 Mar;44(3):143-56. Epub 2004 Apr 30.

PMID:
15309432
44.

Time- and dose-dependent effects of curcumin on gene expression in human colon cancer cells.

Van Erk MJ, Teuling E, Staal YC, Huybers S, Van Bladeren PJ, Aarts JM, Van Ommen B.

J Carcinog. 2004 May 12;3(1):8.

45.

Bromobenzene-induced hepatotoxicity at the transcriptome level.

Heijne WH, Slitt AL, van Bladeren PJ, Groten JP, Klaassen CD, Stierum RH, van Ommen B.

Toxicol Sci. 2004 Jun;79(2):411-22. Epub 2004 Mar 31.

PMID:
15056800
46.

Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells.

van Zanden JJ, Geraets L, Wortelboer HM, van Bladeren PJ, Rietjens IM, Cnubben NH.

Biochem Pharmacol. 2004 Apr 15;67(8):1607-17.

PMID:
15041478
47.

Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin.

Wortelboer HM, Usta M, van der Velde AE, Boersma MG, Spenkelink B, van Zanden JJ, Rietjens IM, van Bladeren PJ, Cnubben NH.

Chem Res Toxicol. 2003 Dec;16(12):1642-51.

PMID:
14680379
48.

Effects of high fat fish oil and high fat corn oil diets on initiation of AOM-induced colonic aberrant crypt foci in male F344 rats.

Dommels YE, Heemskerk S, van den Berg H, Alink GM, van Bladeren PJ, van Ommen B.

Food Chem Toxicol. 2003 Dec;41(12):1739-47.

PMID:
14563399
49.

Quenching of quercetin quinone/quinone methides by different thiolate scavengers: stability and reversibility of conjugate formation.

Awad HM, Boersma MG, Boeren S, Van Bladeren PJ, Vervoort J, Rietjens IM.

Chem Res Toxicol. 2003 Jul;16(7):822-31.

PMID:
12870884
50.

Inhibition of various glutathione S-transferase isoenzymes by RRR-alpha-tocopherol.

van Haaften RI, Haenen GR, van Bladeren PJ, Bogaards JJ, Evelo CT, Bast A.

Toxicol In Vitro. 2003 Jun;17(3):245-51.

PMID:
12781202

Supplemental Content

Loading ...
Support Center